Johnson and Johnson, in a bid to boost its Alzheimer's R&D program, struck a deal potentially worth up to $509 million with Swiss-based biotech AC Immune to develop anti-tau vaccines.
The hope is that therapeutic vaccines targeting tau -- one of two abnormal proteins tied to the memory-robbing disease -- will offer a way to treat Alzheimer’s patients earlier. There is still no treatment that can slow the progression of the disease, with current drugs only easing symptoms of the disorder.
Johnson & Johnson will also further develop AC Immune's lead therapeutic vaccine, ACI-35, which is currently in an early-stage Phase IB clinical trial.
Read the Bidness Etc article
